apitegromab tirzepatide Apitegromab, a selective antimyostatin monoclonal antibody targeting muscle preservation, added to reduced muscle loss by ~55% over 24 weeks without affecting overall weight loss in the phase 2 EMBRAZE trial. https://t.co/jDqTipQrZa GLP-1 drugs effectively and quite
Description
Growth hormone: May improve with weight loss, though effects are variable
doi: 10.1111/obr.13428, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 35
Those metabolic improvements carry real financial value in reduced future healthcare costs, even if that value is difficult to quantify precisely for any individual patient
Now at month ten, I weigh 150 pounds and feel better than I have in fifteen years
Lipid improvements typically become statistically significant by 12-26 weeks
